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To verify whether cystatin C may be of some use as a renal function marker immediately after orthotopic liver
transplantation (OLT), we compared serum cystatin C (SCyst), serum creatinine (Scr), and creatinine clearance (Ccr)
levels with the glomerular filtration rate (GFR). On postoperative days 1, 3, 5, and 7, SCyst and Scr was measured in
simultaneously drawn blood samples, whereas Ccr was calculated using a complete 24-hour urine collection. The GFR
was determined on the same days by means of iohexol plasma clearance (I-GFR). The correlation between 1/SCyst and
I-GFR was stronger than that of 1/Scr or Ccr (P < 0.01). In the case of moderate reductions in I-GFR (80-60
mL/minute/1.73 m2), Scr remained within the normal range, whereas the increase in Scyst was beyond its upper limit;
for I-GFR reductions to lower levels (59-40 mL/minute/1.73 m2), Scr increased slightly, whereas Scyst was twice its
upper normal limit. When we isolated all of the I-GFR values on days 3, 5, and 7 that were >30% lower than that
recorded on the first postoperative day, SCyst (P < 0.0001) and Scr (P < 0.01) levels were increased, whereas Ccr
remained unchanged (P  0.09). Receiver operating characteristic (ROC) area-under-the-curve analysis showed that
the diagnostic accuracy of Scyst was better than that of Scr and Ccr. Scyst levels of 1.4, 1.7, and 2.2 mg/L respectively
predicted I-GFR levels of 80, 60, and 40 mL/minute/1.73 m2. In conclusion, cystatin C is a reliable marker of renal
function during the immediate post-OLT period, especially when the goal is to identify moderate changes in GFR.
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It has been widely demonstrated that acute renal fail-
ure can severely affect the postoperative course of a
complex procedure such as orthotopic liver transplan-
tation (OLT).1,2 As renal function can be threatened for
different reasons in the period immediately following
OLT (i.e., hemodynamic disturbances, drug nephrotox-
icity, acute surgical or infectious complications), it is
very important for clinicians to have access to sensitive
and reliable markers that can promptly identify renal
dysfunction from its initial stage in order to allow them
to adopt the necessary preventive and supportive mea-
sures for avoiding or containing the development of
renal damage.
Although commonly used, the measurement of se-
rum creatinine (Scr) and the calculation of creatinine
clearance (Ccr) are not very reliable in cirrhotic patients
undergoing OLT because some of the peculiarities of the
liver disease (reduced muscle mass, decreased creati-
nine biosynthesis, high blood bilirubin levels) can lead
to false results.3-5 Furthermore, it has been reported
that making routine Scr measurements is an insensitive
way of assessing renal function in patients adminis-
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tered either cyclosporin A or tacrolimus.6 On the other
hand, assessing the glomerular filtration rate (GFR) by
more accurate methods using exogenous markers or
radioisotopes is expensive and hardly practical in the
clinical management of critically ill and unstable pa-
tients. This situation has drawn attention to the use of
an endogenous marker of GFR, such as cystatin C, a
low-molecular-weight polypeptide (13.3 kD) that is
constantly produced by all nucleated cells, freely fil-
tered by glomeruli, and reabsorbed and catabolized in
kidney proximal tubular cells. Consequently, serum
cystatin C (Scyst) concentrations are determined by GFR
regardless of age, gender, muscle mass, or the presence
of inflammatory states.7-11 It has already been shown
that Scyst is a reliable marker of GFR in cirrhotic pa-
tients12-14 and after kidney transplantation.15,16 In re-
lation to OLT, cystatin C has so far been tested in the
later postoperative phase,8,9,17 and so the aim of this
study was to verify whether Scyst may be of some use
also during such a delicate period as the immediate
postoperative phase.
MATERIALS AND METHODS
The study involved a population of post-OLT cirrhotic
patients in an intensive care unit who gave their con-
sent to participate. The only exclusion criterion was the
need for any extra-corporeal renal replacement ther-
apy.
The renal function of all of the enrolled patients was
monitored by measuring Scr, Scyst, and GFR, and by
calculating Ccr, on postoperative days 1, 3, 5, and 7.
Creatinine and cystatin C were measured in simulta-
neously drawn blood samples; Ccr was calculated using
a complete 24-hour urine collection; GFR was mea-
sured by determining iohexol plasma clearance (I-GFR),
and non-age-adjusted values of 80 mL/minute/1.73
m2 were considered compatible with reduced renal
function.8,9
Laboratory Methods
Scr levels were determined by means of Jaffe`’s reaction;
Scyst concentrations were measured by means of latex-
amplified nephelometry using the N Latex Cystatin C
diagnostic kit (Dade Behring Diagnostic, Manheim,
Germany) and the BN-II system (Dade Behring Diag-
nostic, Manheim, Germany). I-GFR was determined by
intravenously administering 5 mL of an Omnipaque
300 solution (Nycomed, Oslo, Norway) containing 647
mg/mL of iohexol (corresponding to 300 mg/mL of io-
dine); the blood samples were taken immediately before
(time 0) and 5, 15, 60, 90, 180, 240, and 300 minutes
after the injection, as previously described.18 If the level
of Scr was 2 mg/dL, 2 further blood samples were
taken 360 and 420 minutes after the injection, and if it
was 5 mg/dL, a final sample was drawn after 1,440
minutes. Plasma iohexol concentrations were deter-
mined in duplicate by means of high-pressure liquid
chromatography (Waters Millipore, Milford, MA) on a
Bondapak C18 inverse phase column (Waters, Milford,
MA). The mobile phase consisted of a 96:4 solution of
bi-distilled water and acetonitrile, pH 2.6. I-GFR was
calculated using the formula I-GFR  injected iohexol
dose/area under the plasma disappearance curve; the
result was corrected by body surface area.19,20 All of the
samples for I-GFR determinations were processed in
the same laboratory.
Concomitant Treatments
Standard perioperative anti-infective prophylaxis con-
sisted of the administration of third-generation cepha-
losporins for 2 days after OLT. Postoperative pain was
controlled by administering intramuscular morphine 1
mg/kg 40 minutes before the end of the procedure,
followed by a continuous intravenous infusion of 20 to
40 mg/day, starting when the patients arrived in the
intensive care unit. The immunosuppressive protocol
included oral cyclosporin A (Sandimmun Neoral, No-
vartis Pharma S.A., Haningue, France) or tacrolimus
(Prograf, Fujisawa, Milano, Italy), methylprednisolone
(Solu-Medrol, Pharmacia & Upjohn, Puurs, Belgium),
and basiliximab (Simulect, Novartis Pharma S.A.,
Haningue, France).
Statistical Analysis
The data are expressed as mean values  standard
deviation unless otherwise specified. We compared I-
GFR with Ccr and the reciprocal values of Scr, and Scyst
(because Scr and cystatin C are inversely related to
GFR) by means of simple regression analyses and cor-
relation coefficient estimates. The significance of the
differences between the correlation coefficients was es-
timated using Fisher’s z-transformation test. Receiver
operating characteristic (ROC) analysis was used to
identify the Scys values that predicted different levels of
renal dysfunction corresponding to I-GFR limits of 80,
60, and 40 mL/minute/1.73 m2. The area under the
ROC curve was used to evaluate the diagnostic accu-
racy of the studied markers. The t-test, the Wilcoxon’s
signed rank test, and the chi-square test were also
used. The statistical analyses were performed using
STATA software (release 7.0, Stata Corporation, College
TABLE 1. Study Population Data
Study population, n 68
Males/females, n (%) 48 (69.7)/20 (30.3)
Age, (range) 50.3  2 (35–61)
Primary liver disease, n (%)
Post-viral infection cirrhosis 54 (79.5)
Alcoholic disease 1 (1.5)
Liver cancer 6 (8.8)
Acute liver failure 2 (2.9)
Other 5 (7.3)
Length of ICU stay, days 4.7  4.6
ICU outcome, alive/dead, n (%) 67/1 (98.5/1.5)
Abbreviation: ICU, intensive care unit.
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Station, TX), and a probability of 5% was considered
significant.
RESULTS
The study involved 68 patients who underwent OLT at
the Liver Transplantation Centres of Pisa (48 patients)
and Turin (20 patients) between August 2003 and
March 2004. Some of the characteristics of the study
population are given in Table 1.
The time-course of each renal function marker is
shown in Table 2. The reciprocal of SCyst and Scr and the
values of Ccr were plotted against I-GFR: the coefficients
of correlation between 1/SCyst and I-GFR on the 4 study
days were 0.80, 0.90, 0.86, and 0.86, those between
1/S
cr
and I-GFR were 0.78, 0.76, 0.51, and 0.61, and
those between Ccr and I-GFR were 0.75, 0.81, 0.37, and
0.60 (Figs. 1-3). The difference in favor of 1/SCyst was
significant in comparison with both 1/Scr and Ccr (P 
0.01 in both cases).
In correspondence with slightly reduced I-GFR values
(80-60 mL/minute/1.73 m2), the levels of Scr remained
within normal limits, whereas those of Scyst were al-
ready high (Table 3). At lower I-GFR levels (59-40 mL/
minute/1.73 m2), Scr levels were slightly increased,
whereas Scyst levels were twice the upper normal limit
(Table 3); in the case of severely reduced GFR levels
(40 mL/minute/1.73 m2), also the levels of Scr be-
came clearly high (Table 3). Finally, the 100 I-GFR val-
ues 80 mL/minute/1.73 m2 (36.7% of the total) mea-
sured during the study corresponded to 51 Scr
determinations within the normal range, but to no nor-
mal determinations of Scyst (P  0.0001) (Fig. 4). How-
ever, the same plot highlights that elevated Scyst values
may be found when GFR is within the normal range.
In order to evaluate the ability of cystatin C to reveal
moderate variations in GFR, we compared the behavior
of the studied markers after having isolated all of the
I-GFR values recorded on days 3, 5, and 7 that were
30% lower than that recorded on the first postopera-
tive day (baseline). Such reductions were observed in 30
subjects (44.1% of the total), where I-GFR passed from
112.7  41.1 to 69.8  28.6 mL/minute/1.73 m2 (P 
0.001). In the 49 corresponding data sets, SCyst in-
creased from 1.1  0.6 to 1.9  0.9 mg/L (P  0.0001)
and Scr from 0.9  0.6 to 1.3  0.8 mg/dL (P  0.01),
with no change in Ccr (from 116.1 53.2 to 94.8 56.1
mL/min; P  0.09). However, in these patients, 33
(67.3%) of the creatinine values were within the normal
TABLE 2. Markers of Renal Function During the Study
POD 1 POD 3 POD 5 POD 7
Serum cystatin C (mg/L) 1.4  0.8 1.7  0.9 1.7  1.1 1.6  1.0
Serum creatinine (mg/dL) 1.0  0.6 1.2  1.3 1.2  1.4 1.2  1.5
Creatinine clearance (mL/minute) 108.6  65.5 114.0  63.7 100.4  55.5 98.1  50.6
I-GFR (mL/minute 1.73 m2) 91.7  43.5 97.1  44.5 89.5  38.4 86.9  32.3
Abbreviations: I-GFR, glomerular filtration rate measured by means of iohexol clearance; POD, postoperative day.
Figure 1. Correlations between
SCyst and I-GFR. I-GFR  GFR
measured by means of iohexol
clearance.
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range, compared to none of the cystatin C values (P 
0.0001). The patients experiencing a reduction in GFR
of30% in comparison with the first day baseline value
were further subdivided on the basis of their initial
I-GFR values (80 and 80 mL/minute/1.73 m2). In
the group with initially normal renal function (n  40),
the levels of I-GFR decreased from 130.04  25.4 to
80.95  21.3 mL/minute/1.73 m2 (P  0.0001), SCys
increased from 1.06  0.55 to 1.86  0.99 mg/L (P 
0.0001), SCr passed from 0.71  0.22 to 1.09  0.42
mg/dL (P  0.0001), and CCr did not change (117.3 
13.3 vs. 116.6  35.7 mL/minute; P  0.9). In the
subjects with initial I-GFR values of 80 mL/minute/
1.73 m2 (n  10), I-GFR decreased from 48.0  22.4 to
30.0  18.4 mL/minute/1.73 m2, SCys increased from
1.5  1.0 to 2.5  1.47 mg/L (P  0.01), and SCr from
1.7  0.9 to 3.1  2.6 mg/mL (P  0.05), whereas, once
again, there was no statistically significant change in
CCr (111.3  52.0 vs. 91.7  57.4 mL/minute; P 
0.09).
The results of the ROC area-under-the-curve analysis
testing the studied markers for their diagnostic accu-
Figure 2. Correlations between
creatinine and I-GFR. I-GFR 
GFR measured by means of io-
hexol clearance; SCreat  Scr.
Figure 3. Relationships be-
tween I-GFR and Ccr. I-GFR 
GFR measured by means of io-
hexol clearance; Creat Clear 
Ccr.
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racy are given in Table 4. Finally, ROC analysis revealed
the Scyst levels that predicted reduced I-GFR values: the
levels maximizing the sensitivity/specificity ratio were
1.4 mg/L (sensitivity, 90.6%; specificity, 85.2%) for I-
GFR values of 80 mL/minute/1.73 m2, 1.7 mg/L
(sensitivity, 96.7%; specificity, 85%) for I-GFR values of
60 mL/minute/1.73 m2, and 2.2 mg/L (sensitivity,
85.7%; specificity, 88.3%) for I-GFR values of 40 mL/
minute/1.73 m2.
DISCUSSION
Cystatin C has been found to be useful in cirrhotic
patients with renal dysfunction10,11,21 and in OLT sub-
jects some time after they have undergone sur-
gery.8,9,17 Now our study highlights its potential in the
immediate post-OLT phase, when hemodynamic or
metabolic disturbances, technical and/or infectious
complications, and the need to keep high blood levels of
the immunosuppressive drugs may cause insidious
variations in GFR. Our results show a better relation-
ship between Scyst and I-GFR than between I-GFR and
SCr or CCr throughout the study period, with signifi-
cantly higher correlation coefficients. Furthermore,
cystatin C accurately and reliably identified moderate
reductions in the GFR. Some of the other characteris-
tics of cystatin C also make it particularly interesting as
a renal function marker in the immediate post-OLT
phase. In fact, in addition to being independent of mus-
cle mass, gender, blood bilirubin levels, and age, Scyst is
unaffected by events that may be frequent after OLT,
such as inflammatory or septic states and/or pharma-
cological or biochemical interferences, unlike other
markers, such as 2-microglobulin, retinal-binding
protein, and  trace protein.10-12,21,23 Cystatin C is
also interesting as a means of monitoring immediate
post-OLT renal function because of the reported
drawbacks of using Ccr and Scr in cirrhotic patients,
making these markers not very sensitive in revealing
slight renal damages.3-6 Furthermore, the reliability
of Scr is undermined by the fact that it increases only
a relatively long time after a reduction in GFR, which
may even need to be as much as 75% before abnormal
values can be seen.22 Finally, the calculation of Ccr
can be unreliable soon after OLT, as it has been found
to overestimate GFR by as much as 504 or 100%6 in
TABLE 3. Variations in Renal Function Markers by I-GFR Ranges
I-GFR
(mL/minute/1.73 m2)
SCr
(mg/dL)
SCyst
(mg/L)
CCr
(mL/minute)
I-GFR 80 mL/minute/1.73m2
(174 measurements)
116.0  26.2 0.7  0.2 1.1  0.3 124.8  51.1
I-GFR  79  60 mL/minute/1.73m2
(50 measurements)
69.7  6.4 1.0  0.2 1.8  0.5 80.4  49.5
I-GFR  59  40 mL/minute/1.73m2
(38 measurements)
50.8  6.7 1.4  0.4 2.3  0.4 61.9  24.1
I-GFR  40 mL/minute/1.73m2
(18 measurements)
30.7  7.2 2.2  1.7 2.9  0.9 32.4  23.6
NOTE: Normal ranges: SCr  0.6–1.3 mg/dL; SCyst  0.5–0.95 mg/L; CCr  65–135 ml/minute.
Abbreviations: I-GFR, glomerular filtration rate measured by means of iohexol clearance; SCr, serum creatinine; SCyst, serum
cystatin C; CCr, creatinine clearance.
Figure 4. Total relationships between Scr , Scyst, and I-GFR.
The broken vertical lines indicate the lower limit of normal
GFR (80mL/minute/1.73m2 ), and the broken horizontal lines
the upper limit of normal Scyst (0.9 mg/L) and Scr (1.3 mg/dL)
levels in our laboratory.
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cirrhotic patients with renal dysfunction, and the
same happens when it is estimated using the Cock-
croft-Gault formula.10 Nevertheless, we do not believe
that creatinine and cystatin C have to be considered
competing markers of renal function in OLT recipi-
ents because our data also confirm the specificity of
Scr and its ability to reveal particularly substantial
changes in GFR. Therefore, measuring SCyst could be
used after OLT, especially in the more severely cir-
rhotic subjects, where Scr can be of little help and
where even a moderate change in GFR may be clini-
cally and prognostically important.11 However, de-
spite these considerations, some data indicate the
need to more deeply investigate the behavior of cys-
tatin C in transplant patients. In fact, it has been
reported that the use of steroids and cyclosporin A
can negatively affect the measurement of cystatin C
in kidney transplant recipients, thus suggesting that
immunosuppression may lead to an overestimate of
GFR.24 Moreover, a study of a small population of
pediatric organ transplant recipients has found
greater intraindividual variations in SCyst than in
SCr
26; finally, a polymorphism of the gene responsible
for the synthesis of cystatin C has been identified that
leads to a genotype-dependent variation in its blood
levels.27 Nevertheless, it must also be considered that
these findings require confirmation in adult and cir-
rhotic patients, and that all of the studies of cystatin
C as an index of renal function in transplant patients
have so far always demonstrated that it is by far the
most sensitive, accurate, and reliable method of de-
tecting slight changes in GFR,8,9,14-17,25 and espe-
cially in more critically ill patients, this justifies its
use despite its higher cost, which, in our case, was
Euro1.9 vs. 0.4/test ($2.2 vs. 0.5).
As cystatin C is still little known and not yet widely
used by transplant clinicians, we used ROC analysis to
identify the SCyst values that, in our experience, indi-
cated different levels of GFR, and found that values of
1.4, 1.7, and 2.2 mg/dL were reliable “alarm bells” for
cutoff points of respectively 80, 60, and 40 mL/
minute/1.73 m2. However, in critically ill patients, it
must always be remembered that it is important to
evaluate biological markers in terms of their variations
over time, because considering only the absolute values
could be sometimes misleading due to possible false
positives and/or negatives.
In conclusion, as the development of acute renal fail-
ure after liver transplantation is still associated with
considerable mortality and morbidity, it is extremely
important to be able to make use of highly sensitive
indicators of GFR in order to identify renal dysfunction
early, assess its severity, evaluate the efficacy of inter-
ventions, or adjust the dose of kidney-eliminated drugs.
In this regard, our results show that cystatin C is an
interesting marker of renal function in the immediate
post-OLT period, also when it is necessary to identify
moderate changes in GFR. However, it would be useful
if expert leaders in the field drew up recommendations
concerning the use of the different renal function bio-
chemical markers in order to guide clinicians and lab-
oratory staff in choosing, in everyday practice, the most
appropriate index according to the different patients
and clinical situations.
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